Hytro has secured patent protection in the United States for its wearable blood flow restriction technology, marking a significant milestone for the UK-based company as it expands into American sports markets. The patent, numbered US 12,317,940, provides intellectual property protection through 2040 for the company’s integrated approach to performance training equipment.
The patent represents the first of its kind for wearable blood flow restriction products in the United States, establishing Hytro as the sole holder of such protection in this category. This legal safeguard arrives as the company builds momentum with professional sports organizations across multiple leagues and disciplines.
Technology Integration Eliminates Traditional Equipment
Hytro’s patented approach embeds adjustable blood flow restriction directly into athletic apparel, removing the need for separate straps or pneumatic systems that typically require expert oversight. This integration allows athletes and coaches to utilize the technology without specialized supervision, broadening accessibility beyond elite training facilities.
The technology addresses practical limitations that have historically confined blood flow restriction training to controlled environments. By incorporating the mechanism into garments, athletes can access the training method across various settings and training scenarios.
Elite Sports Adoption Spans Multiple Disciplines
More than 250 elite teams worldwide currently use Hytro’s products, spanning professional leagues including the Premier League, Premiership Rugby, NFL, NBA, and Formula 1. Individual athletes across boxing, athletics, and tennis have also adopted the technology as part of their training protocols.
Notable organizations using the technology include Manchester City Women‘s FC, England Rugby, and Soudal Quick-Step Cycling. This adoption across diverse sports demonstrates the technology’s versatility in addressing different athletic performance requirements.
The company has already established partnerships with NFL and MLB teams, along with individual players and performance coaches, providing a foundation for expanded American market penetration.
Seven-Year Development Journey Reaches Key Milestone
Dr. Warren Bradley, who founded the company and serves as Head of Elite Performance, filed the original patent application in 2018. “Back in 2018, I filed the original patent for Hytro, pouring all my life’s savings and all my belief into an idea I knew had the power to change how athletes train and recover“ Bradley said.
The patent approval represents validation of the company’s technological approach after years of development and market testing. “We’ve gone from a sketch on paper to a globally recognized product trusted by elite teams and now protected in the biggest market in the world“ Bradley noted.
Market Expansion Strategy Gains Legal Protection
CEO and Co-Founder Raj Thiruchelvarajah emphasized the patent’s strategic importance for market expansion. “This US patent is a huge moment for Hytro. It validates the unique technology we’ve built from day one and protects the innovation that sets us apart in the market“ he said.
The intellectual property protection arrives as Hytro prepares to accelerate growth in American sports markets, building on established relationships with professional teams and performance specialists. The patent provides competitive protection as the company scales operations and develops additional products.
Research Partnerships Support Continued Development
The patent supports ongoing research and development initiatives as Hytro expands its product portfolio. The company maintains collaborations with teams, universities, and research partners across multiple countries, using these relationships to advance blood flow restriction applications.
These partnerships provide scientific validation for the technology while informing product development decisions. The research foundation supports the company’s expansion into new markets and athletic disciplines.
With patent protection secured in the world’s largest sports market, Hytro can pursue American expansion while maintaining competitive advantages in wearable blood flow restriction technology. The legal framework supports both current operations and future product development as the company works to make the training method more accessible to athletes across skill levels.